Navigation Links
OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
Date:8/13/2009

f cancers.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and Isis partnered in the successful discovery of OGX-011, OGX-427 and OGX-225 and with respect to OGX-011, in its initial development. In 2008, OncoGenex and Isis amended their OGX-011 agreement to provide OncoGenex with sole rights to OGX-011 and sole responsibility for development and related costs and partnering decisions, subject to financial obligations to Isis. OncoGenex is also solely responsible for development and related costs and partnering decisions regarding OGX-427 and OGX-225. Key intellectual property related to OGX-011, OGX-427 and OGX-225 were discovered by the University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information about OncoGenex is available at www.oncogenex.com.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
6. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
7. PAREXEL Expands Global Clinical Pharmacology Capabilities
8. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
9. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015 Doctors from ... at Children,s National Health System are ... to treat osteoid osteoma, a benign but painful ... adults, using an experimental magnetic resonance-guided high-intensity focused ultrasound ... and 10-year-old Niyati Shah , have been treated ...
(Date:5/27/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/9ffv95/2015_strategies ... "2015 Strategies in the European Coagulation Testing Market" ... comprehensive five-country report contains 500 pages, 120 tables, ... potential market entrants identify and evaluate business opportunities ... the next five years. The report ...
(Date:5/27/2015)... Research and Markets( http://www.researchandmarkets.com/research/d85hx9/global_rapid ) has announced the addition ... - Applications and Technologies" report to their offering. ... estimated at US$19.4 billion in 2014, forecast at US$20.4 ... CAGR of 5.7% between 2014 and 2020 to reach ... global market for Rapid Medical Diagnostic Kits (MDKs) has ...
Breaking Medicine Technology:Children's National first in US to destroy bone tumors with incisionless surgery 2Children's National first in US to destroy bone tumors with incisionless surgery 3Children's National first in US to destroy bone tumors with incisionless surgery 4European Coagulation Testing Market Strategies 2015 2Global Rapid Medical Diagnostic Kits Market - 2015-2020 Applications and Technologies Analysis of the $27 Billion Industry 2Global Rapid Medical Diagnostic Kits Market - 2015-2020 Applications and Technologies Analysis of the $27 Billion Industry 3Global Rapid Medical Diagnostic Kits Market - 2015-2020 Applications and Technologies Analysis of the $27 Billion Industry 4
... Diagnostics Incorporated (NYSE: DGX ), the world,s ... today it has commenced a tender offer through its ... the outstanding shares of common stock (the "Shares") of ... the world,s pioneers in genetic diagnostics discovery and development ...
... 2011 Bionovo, Inc. (Nasdaq: BNVI ), a ... and effective treatments for women,s health and cancer, today announced ... testing the safety of two doses of Menerba in postmenopausal ... MF101-008), also known as "menopausal hot flashes." ...
Cached Medicine Technology:Quest Diagnostics Commences Tender Offer for Acquisition of Celera 2Quest Diagnostics Commences Tender Offer for Acquisition of Celera 3Bionovo Announces Enrollment Started in the Menerba (MF101) Phase 1 "Tolerability" Clinical Trial for Menopausal Hot Flushes 2Bionovo Announces Enrollment Started in the Menerba (MF101) Phase 1 "Tolerability" Clinical Trial for Menopausal Hot Flushes 3
(Date:5/27/2015)... “ Nursing Homes are starting to supplant hospitals ... of a recent April 2015 New York Times article. While ... the hospital, 20-plus years of research have documented the risks ... nursing homes are both safer for older patients and less ... homes varying widely, patients and family members may worry whether ...
(Date:5/27/2015)... May 27, 2015 In today's healthcare ... tighter, it can be challenging for doctors and hospitals ... edge treatments. , Austin-based HealthTronics, Inc. ... invasive, mobile medical therapies for clinically sophisticated applications. The ... the acquisition of Laser Ventures, Inc ., a ...
(Date:5/27/2015)... Black Book Rankings, well known ... the multiple services and software industries, conducted a ... ranked Electronic Health and Medical Record software systems ... focus on implemented EHR users, Black Book reveals ... the highest scores in client experience among small ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 SAN ... in Gulfport Mississippi, is the first healthcare provider ... approach to chronic care management (CCM). In partnership ... Memorial is introducing RevUp, a new program that ... requirements and increase monthly reimbursements. This new, user-friendly ...
(Date:5/27/2015)... Cincinnati Veterans Affairs Women’s Health Clinic in partnership with ... proud to host the first annual Women Veterans awards ... the Freedom Center from 6 p.m. to 10 p.m. ... , This event honors and celebrates women tri-state Veterans for ... is free to the first 150 women Veterans who register ...
Breaking Medicine News(10 mins):Health News:BestNursingHomes.com Launches on National Senior Health and Fitness Day 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 3Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 2Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 3Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 4Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 2Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 3Health News:Cincinnati VA Women’s Health Clinic Celebrates Women Veterans at Awards Banquet 2
... are frequently used as a replacement for missing teeth ... appearance. Previous research demonstrates that the placement of a ... of the implant, so practitioners often focus their treatment ... tissue surrounding the implant. A recent study published in ...
... Kim Announces the Jobseekers Facelift Giveaway ContestSAN FRANCISCO, May ... David W. Kim has established a Jobseekers Facelift ... number of jobs, older applicants (those over 40) see ... stay competitive with younger applicants. "Of course, one,s accomplishments ...
... Women who take folic acid supplements for at least one ... having a premature baby by half, according to research published ... , The study links pre-conceptional folate supplementation of at least ... to 70 percent, regardless of age, race or other factors. ...
... not prevent spread of waterborne, disease-causing germs.COLORADO SPRINGS, ... ?subject=Swim%20Diaper%20Study" target="_new"> scientific study demonstrates that ... the most common cause of documented recreational water ... Scientists from the University of North Carolina-Charlotte ...
... New treatments are minimally invasive without the side ... video from the Society of Interventional Radiology at: ... CANCER A minimally invasive interventional radiology treatment -- ... as effective as surgery but without the side ...
... the MidwestO,FALLON, Ill. May 12 MEDS, a ... today that it has named G. Scott Dillon ... more than 25 years of experience in clinical ... as chief operating officer of NES Holding Inc. ...
Cached Medicine News:Health News:Placement of dental implants results in minimal bone loss 2Health News:Want to Help Your Job Hunt? Win a Facelift! 2Health News:Taking folic acid for a year before pregnancy may reduce risk of preterm birth 2Health News:New Study: Keep Kids With Diarrhea Out of Pool - Swim Diapers Not Best Solution 2Health News:New Study: Keep Kids With Diarrhea Out of Pool - Swim Diapers Not Best Solution 3Health News:VIDEO from Medialink and the Society of Interventional Radiology: Prostate and Kidney Cancer - New Life-Changing Developments 2Health News:G. Scott Dillon Named President and CEO of MEDS 2
Sebia's Hb AFSC Control provides excellent resolution of normal hemoglobins A & F and abnormal hemoglobins S & C. The control is designed for use with Sebia's Hydragel Hemoglobin and Hydragel Acid He...
The HYRYS™ 2 densitometer is reflective of Sebia's expertise in the development and design of imaging systems and densitometers utilized in the electrophoresis field....
Eliminating the need for any manual pipetting, the HydraPLUS delivers precise micro-volumes of sample directly from primary tubes to four HYDRASYS sample applicators contained in a built-in humidity ...
Inquire...
Medicine Products: